The Conference Forum has announced that the 3rd annual Immuno-Oncology 360° (IO360°) event is expanding to three days and will take place on February 1-3, 2017 at the Roosevelt Hotel in New York City. Led by advisors Dr Axel Hoos (GSK) and Dr James Gulley (NCI), the program provides a unique 360-degree approach, which addresses the most up-to-date information regarding business aspects, clinical advancements and scientific data that will help accelerate clinical trials and FDA approval, ultimately transforming the way cancer is treated. "We are undergoing a radical change in cancer treatment and the biopharma industry needs to gain information that will be beneficial for industry and patients," said Dr Hoos. "The conference will deal with a panoply of topics, including the investment landscape and key business deals, combination immunotherapies and how to test them in clinical trials, and what role the patient can have in clinical designs and recruitment procedures."
The conference will feature keynote addresses on "Clonal Selection of Neo-Antigen Biology" led by Dr Sergio Quezada (University College London Cancer Institute); "Immune Checkpoint Blockade in Cancer Therapies: New Insights and Opportunities for Cures," led by Dr James Allison (MD Anderson Cancer Center); and "A Melanoma Survivor Story: T.J. Sharpe's Immunotherapy Trial Journey," led by T.J. Sharpe (Melanoma Survivor, Advocate and Cancer Blogger). In addition to the keynotes, the conference has plenary sessions designed around:
- Preclinical Science
- Translational Science and New Technologies
- Trends and Collaborations in the IO Space
- Clinical Advancements Parts 1 and 2
- Imaging Methodologies and Techniques for Immunotherapy
- Business Aspects of Immuno-Oncology
IO360° is supported through partnerships with The Association for Cancer Immunotherapy (CIMT), the Cancer Research Institute (CRI), the Patient Empowerment Network (PEN) and the Society of Immunotherapy for Cancer (SITC).
"With the support of CRI, SITC, PEN and CIMT, the IO360° program will help drive the field of cancer immuno-therapy through knowledge sharing and disseminating the most current data, innovative approaches and developments that are changing the way cancer is treated," said Kate Woda, Conference Director.